單株抗體市場規模、佔有率、成長分析，按來源類型、按生產類型、按應用、按最終用途、按地區 - 行業預測，2024-2031 年

2022年全球單株抗體市場規模估值為2,110億美元，預測期間（2024-2031年）複合年成長率為11.5%，從2023年的2,352.7億美元增至2031年的5,620.3億美元，預估也會成長。

單株抗體 (mAb) 是透過克隆特定白血球從單一細胞株產生的抗體。由於其高特異性和功效，這些抗體被用於藥物開發和作為各種疾病的治療劑。全球慢性病盛行率的上升預計將在未來幾年推動單株抗體市場的顯著成長。此外，隨著醫學研發的大量投資以及生物技術的進步，對這些抗體的需求預計將進一步增加。分子生物學的進步預計也將為單株抗體市場做出積極貢獻，促進其銷售和應用。隨著單株抗體在醫療保健、製藥和生物技術領域的應用不斷擴大，該領域的供應商和開發商正在出現新的機會。然而，該市場面臨開發成本高、上市時間長和安全問題等挑戰，可能會阻礙成長。隨著市場的發展，這些因素將繼續成為重要的考慮因素。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 市場生態系統
• 供應鏈分析
• 案例研究分析
• PESTEL分析
• 監管分析
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 競爭程度

單株抗體市場：依來源類型

• 市場概況
• 鼠
• 嵌合體
• 人性化
• 人類

單株抗體市場：依生產類型

• 市場概況
• In vivo
• In vitro

單株抗體市場：依應用分類

• 市場概況
• 腫瘤學
• 自體免疫疾病
• 感染疾病
• 神經系統疾病
• 其他

單株抗體市場：依最終用途分類

• 市場概況
• 醫院
• 專業中心
• 其他

單株抗體市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• GlaxoSmithKline plc（UK）
• Amgen Inc.（US）
• Merck & Co., Inc.（US）
• Daiichi Sankyo Company, Limited（Japan）
• Abbott Laboratories（US）
• AstraZeneca plc（UK）
• Eli Lilly and Company（US）
• Johnson & Johnson Services, Inc.（US）
• Bayer AG（Germany）
• Bristol Myers Squibb（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Viatris Inc.（US）
• Biogen Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• Novo Nordisk A/S（Denmark）
• Sanofi SA（France）
• Merck KGaA（Germany）
• Genmab A/S（Denmark）
• Regeneron Pharmaceuticals, Inc.（US）
• Incyte Corporation（US）

Global Monoclonal Antibodies Market size was valued at USD 211 billion in 2022 and is poised to grow from USD 235.27 billion in 2023 to USD 562.03 billion by 2031, growing at a CAGR of 11.5% during the forecast period (2024-2031).

Monoclonal antibodies (mAbs) are antibodies generated from a single cell lineage by cloning a specific white blood cell. These antibodies are utilized in drug development and as treatments for a variety of diseases due to their high specificity and effectiveness. The increasing prevalence of chronic diseases globally is expected to drive significant growth in the monoclonal antibody market in the coming years. Additionally, substantial investments in medical research and development, along with advancements in biotechnology, are anticipated to further enhance the demand for these antibodies. The progress in molecular biology is also expected to contribute positively to the monoclonal antibody market, boosting their sales and application. As monoclonal antibodies find expanding uses across healthcare, pharmaceuticals, and biotechnology sectors, new opportunities are emerging for suppliers and developers in this field. However, the market faces challenges, including high development costs, extended time-to-market, and safety concerns, which may hinder its growth. These factors are likely to remain key considerations as the market evolves.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segmental Analysis

Global Monoclonal Antibodies Market is segmented by Source type, Production Type, Application, End-use, and region. Based on Source type, the market is segmented into Murine, Chimeric, Humanized, and Human. Based on Production Type, the market is segmented into In Vivo, and In Vitro. Based on Application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, and Others. Based on End-use, the market is segmented into Hospitals, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Monoclonal Antibodies Market

The increasing global prevalence of chronic diseases has heightened the need for innovative treatments and therapeutics, leading to greater investments in medical research and development. Monoclonal antibodies are central to this R&D, offering critical solutions for managing a variety of chronic conditions. As a result, the growing reliance on monoclonal antibodies in the development of new therapies is expected to drive further market expansion. This trend suggests that the market for monoclonal antibodies will continue to grow as research progresses and new applications are discovered.

Restraints in the Global Monoclonal Antibodies Market

The development of monoclonal antibodies involves intricate and time-consuming research techniques, contributing to high R&D costs. These substantial expenses are reflected in the final product prices, which can limit market growth. The elevated cost of developing monoclonal antibodies makes the end products expensive, posing a challenge to market expansion. Consequently, the high development costs are a significant factor impacting the overall growth of the monoclonal antibody market.

Market Trends of the Global Monoclonal Antibodies Market

The expiration of patents for monoclonal antibodies presents promising opportunities for the development of biosimilars and biobetters. Companies can focus their research and development efforts on creating biosimilars for well-established monoclonal antibodies whose patents are nearing expiration. By investing in the development of these biosimilars, companies have the potential to capitalize on the market for these products and achieve significant long-term profits. This strategic move can offer substantial financial benefits as the market for original monoclonal antibodies becomes more competitive.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Ecosystem of the Market
• Supply chain Analysis
• Case study Analysis
• PESTEL Analysis
• Regulatory Analysis
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Monoclonal Antibodies Market by Source type

• Market Overview
• Murine
• Chimeric
• Humanized
• Human

Monoclonal Antibodies Market by Production Type

• Market Overview
• In Vivo
• In Vitro

Monoclonal Antibodies Market by Application

• Market Overview
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

Monoclonal Antibodies Market by End-use

• Market Overview
• Hospitals
• Specialty Centers
• Others

Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments